Journal article
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
BR Stockwell, JP Friedmann Angeli, H Bayir, AI Bush, M Conrad, SJ Dixon, S Fulda, S Gascón, SK Hatzios, VE Kagan, K Noel, X Jiang, A Linkermann, ME Murphy, M Overholtzer, A Oyagi, GC Pagnussat, J Park, Q Ran, CS Rosenfeld Show all
Cell | CELL PRESS | Published : 2017
Abstract
Ferroptosis is a form of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides to lethal levels. Emerging evidence suggests that ferroptosis represents an ancient vulnerability caused by the incorporation of polyunsaturated fatty acids into cellular membranes, and cells have developed complex systems that exploit and defend against this vulnerability in different contexts. The sensitivity to ferroptosis is tightly linked to numerous biological processes, including amino acid, iron, and polyunsaturated fatty acid metabolism, and the biosynthesis of glutathione, phospholipids, NADPH, and coenzyme Q10. Ferroptosis has been implicated in the pathological c..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank The Banbury Center at Cold Spring Harbor Labs for hosting a meeting of the authors that served as the genesis of this manuscript. We thank the following funding organizations: NIH (R35CA209896 and P01 CA087497 to B.R.S.; 4R00CA166517 and 1R01GM122923 to S.J.D.; R01CA171101 to F.M.T.; R01CA188025 to S.V.T.; CA102184 to M.E.M.; HL114453, U19AI068021, NS076511, and NS061817 to V.E.K. and H.B.; R01GM115366 and 1R01GM118730 to K.A.W.; R01CA204232 and P30CA008748 to X.J.; and R01CA160417 to D.T.), JSPS KAKENHI (JP16K15257 and JP17H04064 to S.V.T.), ACS (RSG-16-014-01-CDD to D.T.), NNSFC (2016A030308011 and 31671435 to D.T.), Geoffrey Beene Cancer Research Center grant to X.J., and HFSP (RGP 0013/14 to M.C. and V.E.K.). C.S.R. is an employee of and has a profit interest in Collaborative Medicinal Development. K.N. is a paid consultant of and has a profit interest in Collaborative Medicinal Development. A.I.B. is a shareholder in Prana Biotechnology, Mesoblast, Grunbiotics Pty, and Cogstate and is a paid consultant for and has a profit interest in Collaborative Medicinal Development.